Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anti-CD19/CD20/CD22 CAR-T Cells |
Synonyms | |
Therapy Description |
Anti-CD19/CD20/CD22 CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, CD20, and CD22, which may induce antitumor activity (Blood (2022) 140 (Supplement 1): 7474–7475). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-CD19/CD20/CD22 CAR-T Cells | CD19 Immune Cell Therapy 62 CD20 Immune Cell Therapy 11 CD22 Immune Cell Therapy 15 | Anti-CD19/CD20/CD22 CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, CD20, and CD22, which may induce antitumor activity (Blood (2022) 140 (Supplement 1): 7474–7475). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05418088 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | Recruiting | USA | 0 |